The etiology of cardiac hypertrophy in infants

Código QR

The etiology of cardiac hypertrophy in infants

Abstract This study aimed to describe the variety of etiologies currently identified in infants with cardiac hypertrophy (CH) and investigate whether there is a relation with hyperinsulinism, echocardiographic characteristics and prognosis. This retrospective cohort study included infants born betwe...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Raymond Stegeman, Nina D. Paauw, Rosalie de Graaf, Rosa L. E. van Loon, Jacqueline U. M. Termote, Johannes M. P. J. Breur
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/8a59adf57ea541cf85c61b74b3c51427
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Wild type transthyretin cardiac amiloidozis as a rare and overlooked underlying etiology in a patient with heart failure with preserved ejection fraction and left ventricular hypertrophy
por: Selda Murat, et al.
Publicado: (2021)

Suppressor of IKKɛ is an essential negative regulator of pathological cardiac hypertrophy
por: Ke-Qiong Deng, et al.
Publicado: (2016)

Cardiac-specific microRNA-125b deficiency induces perinatal death and cardiac hypertrophy
por: Chen-Yun Chen, et al.
Publicado: (2021)

AMPK activation counteracts cardiac hypertrophy by reducing O-GlcNAcylation
por: Roselle Gélinas, et al.
Publicado: (2018)

Genetic contributions to the expression of acquired causes of cardiac hypertrophy in non-ischemic sudden cardiac death victims
por: Lauri Holmström, et al.
Publicado: (2021)

Cardiomyocyte gene programs encoding morphological and functional signatures in cardiac hypertrophy and failure
por: Seitaro Nomura, et al.
Publicado: (2018)

Context-independent essential regulatory interactions for apoptosis and hypertrophy in the cardiac signaling network
por: Jun Hyuk Kang, et al.
Publicado: (2017)

The plasma membrane calcium ATPase 4 signalling in cardiac fibroblasts mediates cardiomyocyte hypertrophy
por: Tamer M. A. Mohamed, et al.
Publicado: (2016)

Amalaki rasayana, a traditional Indian drug enhances cardiac mitochondrial and contractile functions and improves cardiac function in rats with hypertrophy
por: Vikas Kumar, et al.
Publicado: (2017)

Cardiac ankyrin repeat protein attenuates cardiac hypertrophy by inhibition of ERK1/2 and TGF-β signaling pathways.
por: Yao Song, et al.
Publicado: (2012)

Histone lysine dimethyl-demethylase KDM3A controls pathological cardiac hypertrophy and fibrosis
por: Qing-Jun Zhang, et al.
Publicado: (2018)

DIOL triterpenes block profibrotic effects of angiotensin II and protect from cardiac hypertrophy.
por: Ruben Martín, et al.
Publicado: (2012)

PEG-coated gold nanoparticles attenuate β-adrenergic receptor-mediated cardiac hypertrophy
por: Qiao YH, et al.
Publicado: (2017)

Iron overload exacerbates age-associated cardiac hypertrophy in a mouse model of hemochromatosis
por: Abitha Sukumaran, et al.
Publicado: (2017)

Sleeve Gastrectomy Ameliorates Diabetes-Induced Cardiac Hypertrophy Correlates With the MAPK Signaling Pathway
por: Qian Xu, et al.
Publicado: (2021)

THE FEATURES OF HUMORAL IMMUNE RESPONSE FOR ANTIGENS OF OPPORTUNISTIC MICROORGANISMS IN CASE OF PHARYNX TONSILS HYPERTROPHY IN INFANTS AND PRESCHOOL CHILDREN
por: E. V. Shabaldina, et al.
Publicado: (2014)

Cardiac emergencies in neonates and young infants
por: Nasib Kabbani, et al.
Publicado: (2017)

Loss of Endothelial Hypoxia Inducible Factor‐Prolyl Hydroxylase 2 Induces Cardiac Hypertrophy and Fibrosis
por: Zhiyu Dai, et al.
Publicado: (2021)

Dual Activity of Ginsenoside Rb1 in Hypertrophic Cardiomyocytes and Activated Macrophages: Implications for the Therapeutic Intervention of Cardiac Hypertrophy
por: Wang S, et al.
Publicado: (2021)

A microRNA program regulates the balance between cardiomyocyte hyperplasia and hypertrophy and stimulates cardiac regeneration
por: Andrea Raso, et al.
Publicado: (2021)

Impaired Cardiac Sympathetic Innervation Increases the Risk of Cardiac Events in Heart Failure Patients with Left Ventricular Hypertrophy and Mechanical Dyssynchrony
por: Takahiro Doi, et al.
Publicado: (2021)

Mapping drug-target interactions and synergy in multi-molecular therapeutics for pressure-overload cardiac hypertrophy
por: Aparna Rai, et al.
Publicado: (2021)

Circ-SIRT1 inhibits cardiac hypertrophy via activating SIRT1 to promote autophagy
por: Weichen Wang, et al.
Publicado: (2021)

Linking type 2 diabetes mellitus, cardiac hypertrophy and depression in a diurnal animal model
por: Carmel Bilu, et al.
Publicado: (2019)

Three TF Co-expression Modules Regulate Pressure-Overload Cardiac Hypertrophy in Male Mice
por: Yao-Ming Chang, et al.
Publicado: (2017)

Differential and conditional activation of PKC-isoforms dictates cardiac adaptation during physiological to pathological hypertrophy.
por: Shaon Naskar, et al.
Publicado: (2014)

Ang-(1-7) is an endogenous β-arrestin-biased agonist of the AT1 receptor with protective action in cardiac hypertrophy
por: Larissa B. Teixeira, et al.
Publicado: (2017)

Inhibition of GTPase Rac1 expression by vitamin D mitigates pressure overload-induced cardiac hypertrophy
por: Ali Moradi, et al.
Publicado: (2021)

A novel PRKAG2 mutation in a Chinese family with cardiac hypertrophy and ventricular pre-excitation
por: Kun-Qi Yang, et al.
Publicado: (2017)

Increased cardiac myocyte PDE5 levels in human and murine pressure overload hypertrophy contribute to adverse LV remodeling.
por: Sara Vandenwijngaert, et al.
Publicado: (2013)

Cellular interplay via cytokine hierarchy causes pathological cardiac hypertrophy in RAF1-mutant Noonan syndrome
por: Jiani C. Yin, et al.
Publicado: (2017)

Terrorism Etiology
por: Alexander Ivanovich Kugay
Publicado: (2018)

Discrepancy between left ventricular hypertrophy by echocardiography and electrocardiographic hypertrophy: clinical characteristics and outcomes
por: Takao Kato, et al.
Publicado: (2021)

The ubiquitin E3 ligase TRAF6 exacerbates pathological cardiac hypertrophy via TAK1-dependent signalling
por: Yan-Xiao Ji, et al.
Publicado: (2016)

Knockout of AMPKα2 Blocked the Protection of Sestrin2 Overexpression Against Cardiac Hypertrophy Induced by Pressure Overload
por: Nan Zhang, et al.
Publicado: (2021)

A Peptide-Functionalized Magnetic Nanoplatform-Loaded Melatonin for Targeted Amelioration of Fibrosis in Pressure Overload-Induced Cardiac Hypertrophy
por: Zhao X, et al.
Publicado: (2020)

The etiology of resilience to disadvantage
por: Alexandra Y. Vazquez, et al.
Publicado: (2021)

Etiology of Uveitis in Upper Egypt
por: Abd El Latif E, et al.
Publicado: (2021)

Protocatechuic acid attenuates isoproterenol-induced cardiac hypertrophy via downregulation of ROCK1–Sp1–PKCγ axis
por: Liyan Bai, et al.
Publicado: (2021)

Automated Medical Care: Bradycardia Detection and Cardiac Monitoring of Preterm Infants
por: Beatrice Arvinti, et al.
Publicado: (2021)